Last reviewed · How we verify
Chloromycetin (chloramphenicol succinate)
Chloromycetin (chloramphenicol succinate) is a small molecule antibiotic in the Amphenicol-class, originally developed and currently owned by Parkedale. It was FDA-approved in 1950 for the treatment of Salmonella infection and Typhoid fever. Chloromycetin works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection. As a patented product, its commercial status is not generic. Key safety considerations include potential bone marrow suppression and grey baby syndrome.
At a glance
| Generic name | chloramphenicol succinate |
|---|---|
| Sponsor | Parkedale |
| Drug class | Amphenicol-class Antibacterial |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Salmonella infection
- Typhoid fever
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Glossitis
- Stomatitis
- Enterocolitis
- Headache
- Mild depression
- Mental confusion
- Delirium
- Fever
- Macular rashes
Serious adverse events
- Aplastic anemia
- Bone marrow depression
- Hypoplastic anemia
- Thrombocytopenia
- Granulocytopenia
- Pancytopenia
- Gray syndrome
- Optic neuritis
- Peripheral neuritis
- Anaphylaxis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloromycetin CI brief — competitive landscape report
- Chloromycetin updates RSS · CI watch RSS
- Parkedale portfolio CI